This brand name is authorized in Estonia, Poland
The drug POLIORIX contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Inactivated poliovirus type 1 (Mahoney strain)
UNII 0LVY784C09 - POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED)
|
|
|
|
2
Inactivated poliovirus type 2 (strain MEF-1)
UNII 23JE9KDF4R - POLIOVIRUS TYPE 2 ANTIGEN (FORMALDEHYDE INACTIVATED)
|
|
|
|
3
Inactivated poliovirus type 3 (Saukett strain)
UNII 459ROM8M9M - POLIOVIRUS TYPE 3 ANTIGEN (FORMALDEHYDE INACTIVATED)
|
|
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J07BF03 | Poliomyelitis, trivalent, inactivated, whole virus | J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BF Poliomyelitis vaccines |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EE | Ravimiamet | Identifier(s): 1136012, 1136023, 1398506 |
| Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100223375 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
